Methotrexate/Misoprostol Embryopathy: Report of Four Cases Resulting From Failed Medical Abortion

American Journal of Medical Genetics

Volumn 123 A, Issue 1, 2003, Pages 72-78

  Adam, Margaret P ^a   Manning, Melanie A ^a   Beck, Anita E ^a   Kwan, Andrea ^a   Enns, Gregory M ^a   Clericuzio, Carol ^b   Hoyme, H Eugene ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Abortifacients; Human teratology; Medical abortion; Methotrexate embryopathy; Misoprostol embryopathy

Indexed keywords

METHOTREXATE; MISOPROSTOL;

ARTICLE; CASE REPORT; ECTOPIC PREGNANCY; EMBRYOPATHY; GROWTH RETARDATION; HEALTH CARE PERSONNEL; HUMAN; INDUCED ABORTION; MALE; MEDICAL SPECIALIST; NEWBORN; PARAMETER; PATIENT COUNSELING; PHYSICIAN; PREGNANCY; PRENATAL DRUG EXPOSURE; PRIORITY JOURNAL; RISK; TERATOGENESIS; TERATOLOGY;

HUMAN ECHOVIRUS 1;

EID: 0142200983     PISSN: 15524825     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.a.20503     Document Type: Article

References (26)

1. Bawle EV, Conard JV, Weiss L. 1998. Adult and two children with fetal methotrexate syndrome. Teratology 57:51-55.
2. Blatt J, Mulvihill JJ, Ziegler JL, Young RC, Poplack DG. 1980. Pregnancy outcome following cancer chemotherapy. Am J Med 69:828-832.
3. Buckley LM, Bullaboy CA, Leichtman L, Marquez M. 1997. Multiple congenital anomalies associated with weekly low-dose methotrexate treatment of the mother. Arthritis Rheum 40:971-973.
4. Castilla EE, Orioli IM. 1994. Teratogenicity of misoprostol: Data from the Latin-American collaborative study of congenital malformations (ECLAMC). Am J Med Genet 51:161-162.
5. Coelho KE, Sarmento MF, Veiga CM, Speck-Martins CE, Safatle HP, Castro CV, Niikawa N. 2000. Misoprostol embryotoxicity: Clinical evaluation of fifteen patients with arthrogryposis. Am J Med Genet 95:297-301.
6. Del Campo M, Kosaki K, Bennett FC, Jones KL. 1999. Developmental delay in fetal aminopterin/methotrexate syndrome. Teratology 60: 10-12.
7. Donnenfeld AE, Pastuszak A, Noah JS, Schick B, Rose NC, Koren G. 1994. Methotrexate exposure prior to and during pregnancy. Teratology 49:79-81.
8. Feldkamp M, Carey JC. 1993. Clinical teratology counseling and consultation case report: Low dose methotrexate exposure in the early weeks of pregnancy. Teratology 47:533-539.
9. Fonseca W, Alencar AJ, Mota FS, Coelho HL. 1991. Misoprostol and congenital malformations. Lancet 338:56.
10. Goldberg AB, Greenberg MB, Darney PD. 2001. Misoprostol and pregnancy. N Engl J Med 344:38-47.
11. Gonzalez CH, Vargas FR, Perez AB, Kim CA, Brunoni D, Marques-Dias MJ, Leone CR, Correa Neto J, Llerena Junior JC, de Almeida JC. 1993. Limb deficiency with or without Möbius sequence in seven Brazilian children associated with misoprostol use in the first trimester of pregnancy. Am J Med Genet 47:59-64.
12. Gonzalez CH, Marques-Dias MJ, Kim CA, Sugayama SM, Da Paz JA, Huson SM, Holmes LB. 1998. Congenital abnormalities in Brazilian children associated with misoprostol misuse in first trimester of pregnancy. Lancet 351:1624-1627.
13. Hofmeyr GJ, Milos D, Nikodem VC, de Jager M. 1998. Limb reduction anomaly after failed misoprostol abortion. S Afr Med J 88:566-567.
14. Krahenmann F, Ostensen M, Stallmach T, Huch A, Chaoui R. 2002. In utero first trimester exposure to low-dose methotrexate with increased fetal nuchal translucency and associated malformations. Prenat Diagn 22:489-490.
15. Milunsky A, Graef JW, Gaynor MF Jr. 1968. Methotrexate-induced congenital malformations. J Pediatr 72:790-795.
16. Nguyen C, Duhl AJ, Escallon CS, Blakemore KJ. 2002. Multiple anomalies in a fetus exposed to low-dose methotrexate in the first trimester. Obstet Gynecol 99:599-602.
17. Orioli IM, Castilla EE. 2000. Epidemiological assessment of misoprostol teratogenicity. Bjog 107:519-523.
18. Ostensen M, Hartmann H, Salvesen K. 2000. Low dose weekly methotrexate in early pregnancy. A case series and review of the literature. J Rheumatol 27:1872-1875.
19. Pastuszak AL, Schuler L, Speck-Martins CE, Coelho KE, Cordello SM, Vargas F, Brunoni D, Schwarz IV, Larrandaburu M, Safattle H, et al. 1998. Use of misoprostol during pregnancy and Möbius' syndrome in infants. N Engl J Med 338:1881-1885.
20. Powell HR, Ekert H. 1971. Methotrexate-induced congenital malformations. Med J Aust 2:1076-1077.
21. Rubaltelli FF, Mittiga S, Solito P. 1982. Growth and development of children born to mothers treated with cytotoxic drugs during pregnancy. Helv Paediatr Acta 37:599-601.
22. Schuler L, Ashton PW, Sanseverino MT. 1992. Teratogenicity of misoprostol. Lancet 339:437.
23. Schuler L, Pastuszak A, Sanseverino TV, Orioli IM, Brunoni D, Ashton-Prolla P, Silva da Costa F, Giugliani R, Couto AM, Brandao SB, et al. 1999. Pregnancy outcome after exposure to misoprostol in Brazil: A prospective, controlled study. Reprod Toxicol 13:147-151.
24. Singh K, Fong YF, Dong F. 2003. A viable alternative to surgical vacuum aspiration: Repeated doses of intravaginal misoprostol over 9 h for medical termination of pregnancies up to 8 weeks. Bjog 110:175-180.
25. Vargas FR, Schuler-Faccini L, Brunoni D, Kim C, Meloni VF, Sugayama SM, Albano L, Llerena JC Jr, Almeida JC, Duarte A, et al. 2000. Prenatal exposure to misoprostol and vascular disruption defects: A case-control study. Am J Med Genet 95:302-306.
26. Wheeler M, O'Meara P, Stanford M. 2002. Fetal methotrexate and misoprostol exposure: The past revisited. Teratology 66:73-76.